These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23977020)

  • 1. Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease.
    Li X; Redus L; Chen C; Martinez PA; Strong R; Li S; O'Connor JC
    PLoS One; 2013; 8(8):e71341. PubMed ID: 23977020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Langley MR; Ghaisas S; Palanisamy BN; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Exp Neurol; 2021 Jul; 341():113716. PubMed ID: 33839143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
    Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
    J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.
    Lynch WB; Tschumi CW; Sharpe AL; Branch SY; Chen C; Ge G; Li S; Beckstead MJ
    Mov Disord; 2018 Dec; 33(12):1928-1937. PubMed ID: 30440089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease.
    Fifel K; Cooper HM
    Neurobiol Dis; 2014 Nov; 71():359-69. PubMed ID: 25171792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
    Langley M; Ghosh A; Charli A; Sarkar S; Ay M; Luo J; Zielonka J; Brenza T; Bennett B; Jin H; Ghaisas S; Schlichtmann B; Kim D; Anantharam V; Kanthasamy A; Narasimhan B; Kalyanaraman B; Kanthasamy AG
    Antioxid Redox Signal; 2017 Nov; 27(14):1048-1066. PubMed ID: 28375739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
    Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
    Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.
    Grauer SM; Hodgson R; Hyde LA
    Psychopharmacology (Berl); 2014 Apr; 231(7):1325-37. PubMed ID: 24150248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.
    Good CH; Hoffman AF; Hoffer BJ; Chefer VI; Shippenberg TS; Bäckman CM; Larsson NG; Olson L; Gellhaar S; Galter D; Lupica CR
    FASEB J; 2011 Apr; 25(4):1333-44. PubMed ID: 21233488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.
    Galter D; Pernold K; Yoshitake T; Lindqvist E; Hoffer B; Kehr J; Larsson NG; Olson L
    Genes Brain Behav; 2010 Mar; 9(2):173-81. PubMed ID: 20002202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
    Gellhaar S; Marcellino D; Abrams MB; Galter D
    Genes Brain Behav; 2015 Mar; 14(3):260-70. PubMed ID: 25752644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
    Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
    PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's Disease.
    Cong L; Muir ER; Chen C; Qian Y; Liu J; Biju KC; Clark RA; Li S; Duong TQ
    PLoS One; 2016; 11(3):e0151884. PubMed ID: 27003179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Beckstead MJ; Howell RD
    Exp Neurol; 2021 Jul; 341():113707. PubMed ID: 33753138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.
    Ghaisas S; Langley MR; Palanisamy BN; Dutta S; Narayanaswamy K; Plummer PJ; Sarkar S; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2019 Dec; 75():186-199. PubMed ID: 31505196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease.
    Rial D; Castro AA; Machado N; Garção P; Gonçalves FQ; Silva HB; Tomé AR; Köfalvi A; Corti O; Raisman-Vozari R; Cunha RA; Prediger RD
    PLoS One; 2014; 9(12):e114216. PubMed ID: 25486126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-motor and motor features in LRRK2 transgenic mice.
    Bichler Z; Lim HC; Zeng L; Tan EK
    PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.
    Adeosun SO; Hou X; Zheng B; Melrose HL; Mosley T; Wang JM
    Neurobiol Learn Mem; 2017 Jul; 142(Pt B):182-189. PubMed ID: 28487191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
    Wood NI; Glynn D; Morton AJ
    Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.